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Abstract
The replacement of “presumptive treatment for malaria” by “test before treat” strategies for the 
management of febrile illness is raising awareness of the importance of knowing more about the 
causes of illness in children who are suspected to have malaria but return a negative 
parasitological test. The most common cause of non-malarial febrile illness (NMFI) in African 
children is respiratory tract infection. Whilst the bacterial causes of NMFI are well known, the 
increasing use of sensitive techniques such as polymerase chain reaction (PCR) tests is revealing 
large numbers of viruses that are potential respiratory pathogens. However, many of these 
organisms are commonly present in the respiratory tract of healthy children so causality and risk 
factors for pneumonia remain poorly understood. Infection with a combination of viral and 
bacterial pathogens is increasingly recognised as important in the pathogenesis of pneumonia. 
Similarly, blood stream infections with organisms typically grown by aerobic culture are well 
known but a growing number of organisms that can be identified only by PCR, viral culture, or 
serology are now recognised to be common pathogens in African children. The high mortality of 
hospitalised children on the first or second day of admission suggests that, unless results are 
rapidly available, diagnostic tests to identify specific causes of illness will still be of limited use in 
guiding the potentially life saving decisions relating to initial treatment of children admitted to 
district hospitals in Africa with severe febrile illness and a negative test for malaria. Malaria 
control and the introduction of vaccines against Haemophilus influenzae type b and pneumococcal 
disease are contributing to improved child survival in Africa. However, increased parasitological 
testing for malaria is associated with increased use of antibiotics to which resistance is already 
high.
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1. Introduction
Interest in non-malarial febrile illness (NMFI) has increased following more widespread use 
of parasitological testing for malaria and, in particular, since 2010 when the World Health 
Organization (WHO) recommendation for antimalarial treatment for any unexplained fever 
was replaced by the recommendation that, wherever possible, antimalarial treatment should 
be restricted to children with a positive parasitological test [1,2]. Support for this policy by a 
number of major funders, including the Global Fund to Fight AIDS, Tuberculosis and 
Malaria, is having a major impact on case management of fevers in Africa. In the WHO 
Africa region, the number of rapid diagnostic tests (RDTs) for malaria that were distributed 
through national malaria control programmes rose from less than 2 million in 2006 to more 
than 80 million in 2012 [3]. Over the same period, the proportion of suspected malaria cases 
that received a diagnostic test rose from an estimated 20% to 60% [3]. Consequently, these 
developments are generating large numbers of patients who were previously treated for 
malaria but are now being considered for treatment of an alternative cause of fever [4].
The definition of NMFI is pragmatic but it remains a useful term in a period of transition 
from presumptive to more targeted treatment of febrile illness in African children. The term 
describes the situation of a patient with suspected malaria and a negative parasitological test. 
Like many causes of fever, malaria is an illness with clinical features that often overlap with 
other common causes of fever [5]. The most common of these is respiratory tract infection 
since fever can cause rapid breathing in children [6–8], and acidosis (commonly found in 
children with severe malaria) can cause deep laboured breathing with abnormal chest wall 
movement [8,9]. In addition, the features of cerebral malaria can be similar to those of 
meningitis [10], and fever without specific features can resemble non-severe malaria [11]. 
Diarrhoeal diseases rarely cause diagnostic confusion and so are not considered under 
NMFI. Similarly, otitis media or urinary tract infections usually present with clinical 
features that generally do not overlap with those of malaria. Low density Plasmodium 
parasitaemia may occur in the neonatal period but is usually asymptomatic due to the 
presence of maternal antibody and rarely meets our definition of NMFI [12]. Thus neonatal 
pneumonia, an important but specialised topic, is outside the scope of this review.
This review describes the main causes of NMFI in African children, with an emphasis on 
acute lower respiratory tract infections. Systematic testing of children for human 
immunodeficiency virus (HIV) is still not commonly practiced in Africa so there are few 
studies comparing causes of fever in children with or without HIV. The prevalence of HIV 
in hospitalised children varies between 1% and 17% in areas highly endemic for malaria but 
is considerably less in children presenting to outpatient clinics [13,14]. In this review, HIV-
infected children have not been excluded and HIV data are shown where available.
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2. Diagnostic accuracy, overlapping definitions, and co-infection
A definitive diagnosis of malaria is often difficult due to a number of reasons [15], the best 
known of which is that Plasmodium parasitaemia may be present as an incidental finding in 
a child with fever due to another cause. Determination of parasite density, which influences 
the attributable fraction of fever due to malaria, can be of help: The presence of parasites at 
high density make malaria more likely to be the cause of a child’s illness than a low density 
infection, but this relationship is influenced by the level of malaria endemicity [16,17]. In 
addition, blood slide diagnosis may miss true P. falciparum infections due to either parasite 
sequestration or very low density parasitaemia, although true “slide-negative malaria” is 
probably rare. RDTs for malaria are not affected by parasite sequestration since they 
measure water-soluble parasite antigens but, in areas of high transmission, devices that 
detect histidine-rich protein-2 (HRP-2) may lack specificity due to the persistence of HRP-2 
in blood for up to 6 weeks following infection [18,19]. Finally, up to 10% of children with 
severe malaria also have a blood stream bacterial infection, a fact that has led some to 
recommend antibacterial treatment of all children with severe malaria [13,20]. While some 
of these cases may be due to incidental parasitaemia, it is now well established that malaria 
itself is an important risk factor for non-typhi Salmonella (NTS) and other Gram-negative 
infections [21,22].
3. Pneumonia in African children
Pneumonia is the most common alternative diagnosis to malaria in a febrile child in Africa 
[8,9]. The global incidence of hospital admissions of children with severe ALRI (including 
pneumonia and bronchiolitis) is age-dependent: it is highest in children under the age of 2 
years [23] and substantially higher in developing compared to industrialised countries, but 
similar between Asia and Africa [23,24]; however, hypoxaemia in children meeting WHO 
definitions of pneumonia severity [25] is more common in Asia [26] (possibly due to 
misclassification of children with malarial acidosis as severe pneumonia). Thirty-eight 
percent of childhood cases of severe ALRI do not reach hospital, and 81% of those severe 
ALRI cases result in death: substantially higher than in children hospitalised with severe 
ALRI [23]. This estimate was based on verbal autopsy and should therefore be treated with 
caution.
3.1 Pneumonia case definitions
The study of pneumonia suffers from, among other things, difficulties in obtaining a culture 
specimen from the site of infection and variation in case definitions [27], the former of 
which is currently being, at least to some extent, addressed by the study of Pneumonia 
Etiology Research for Child Health (PERCH)(Table 1) [33].
The selection of case definition depends on available diagnostic resources and priority for 
either high specificity (needed for clinical trials) or high sensitivity (needed for treatment of 
sick children) (Table 2). In most areas of Africa, the WHO definitions for severe pneumonia 
(cough and difficulty breathing with lower chest wall indrawing) and very severe pneumonia 
(cough and difficulty breathing with danger signs) [25] are generally followed, of which the 
definition of severe pneumonia is used most commonly. Raised respiratory rate (RR) or 
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chest wall indrawing have a sensitivity and specificity of approximately 81% and 77%, 
respectively, when compared to paediatrician diagnosis of pneumonia supported by chest 
roentgenogram [31]. In contrast to definitions of severe pneumonia, there is only one 
definition of the WHO category of “non-severe pneumonia” (cough or difficulty in 
breathing with raised RR for age) but the significance of this as a risk factor for progression 
to severe pneumonia is not clear. While some studies have shown a correlation between 
raised RR and severe pneumonia [31,37], a placebo-controlled trial of amoxicillin in 
children with nonsevere pneumonia in Pakistan [38] failed to show a significant difference 
between trial arms, suggesting either that non-severe pneumonia may in the large majority 
of cases be due to a viral infection alone or the low specificity of the WHO definition of 
non-severe pneumonia includes many illnesses with a non-respiratory cause.
A number of studies, summarised by Rudan et al [24], have described predictors of mortality 
among African children with pneumonia that include malnutrition, HIV infection, subcostal 
recession, and altered consciousness. The latter 2 factors are reflected in the increased 
mortality associated with the WHO classification of “very severe” compared to “severe” 
pneumonia, respectively [39]. In addition, access to care is an important determinant of 
survival in children with pneumonia [23].
3.2 Burden and causes of pneumonia in African children
Estimating incidence and causes of pneumonia in Africa is difficult due to the problems 
already mentioned, compounded by the few high quality laboratories in Africa and the 
changing epidemiology created by vaccines and availability of polymerase chain reaction 
(PCR) methodologies. For more than a decade, the Child Health Epidemiology Reference 
Group (CHERG)—a group of independent technical experts on global child morbidity and 
mortality estimates co-sponsored by WHO and UNICEF—has grappled with these 
problems. The 2013 CHERG estimates are based on a model using estimates of prevalence 
of known risk factors, incidence data from control arms of pneumonia clinical trials [40], 
and results from 28 pneumonia incidence studies that met minimum inclusion criteria [41]. 
Even among these estimates, the incidence of pneumonia varied 100-fold, reflecting both 
true variation but also lack of standardisation between studies. The CHERG estimates are 
summarised in Table 3. The 3 subsequent tables have been selected from published studies 
to illustrate specific issues with assigning causality to pneumonia in Africa, that is, the 
availability of PCR and the frequency of carriage of viral pathogens among healthy controls.
Table 4 is reproduced from a recent study in Malawi [42] demonstrating the range of 
pathogens commonly identified in African children admitted to hospital with severe 
pneumonia, albeit in an area of relatively high HIV prevalence. In addition, this study 
highlights the greatly increased sensitivity of PCR in detecting respiratory pathogens, 
although since the upper respiratory tract is not a “normally sterile site” the interpretation of 
the presence of these pathogens is challenging.
3.2.1 Bacterial pneumonia—The incidence of pneumonia due to Streptococcus 
pneumoniae or Haemophilus influenzae type b (Hib) is changing as vaccines against these 
infections are now being introduced across the continent. Currently, all African countries 
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have introduced Hib conjugate vaccine in infants and all but 2 sub-Saharan African 
countries have introduced or are in the process of introducing infant vaccination using a 10- 
or 13-valent pneumococcal conjugate vaccine (PCV-10 or PCV-13) [43].
The high efficacy of these vaccines in African children has been established in clinical trials 
[34,36,44]. The effectiveness of the Hib conjugate vaccine is encouraging, with reports of 
reductions to near-zero incidence of invasive Hib disease following vaccination, although 
questions remain regarding the duration of protection following immunisation in infancy 
[45,46].
The impact of PCV-10 is still being assessed and no large studies have so far been 
published. In a district hospital on the Kenyan coast, paediatric admissions for invasive 
pneumococcal disease (IPD) from the nearby demographic surveillance system have been 
continuously monitored since 2003. There was a 50% reduction in admissions with IPD 
between 2003 and 2007 that may have been due to the reduction in malaria incidence that 
occurred between these years [22,47]. PCV-10 was first introduced to the childhood 
immunisation schedule in 2011. It is likely that PCV will bring additional benefits of 
secondary protection of older (unvaccinated) family members from IPD although there is 
also evidence of increased colonisation by non-vaccine strains of S. pneumoniae [46].
Staphylococcus aureus and Gram-negative infections are important, albeit in the minority, 
causes of bacterial pneumonia. Staphylococcal pneumonia is often very severe and may 
affect very young children. Nosocomial transmission of methicillin-resistant S. aureus is a 
particular problem in intensive care units and has been described in Ghana, although its 
routine detection in Africa is almost certainly hampered by lack of laboratory capacity [48]. 
Strains of S. aureus carrying the Panton-Valentine leukocidin genes cause a particularly 
severe form of pneumonia; while most reports of this organism are from developed 
countries, there is at least one case report of a fatal infection in a traveller returning from 
Senegal [49].
Gram-negative infections, and in particular NTS, are associated with malaria (as described 
below) and many of these qualify for the WHO definition of severe pneumonia. While this 
definition lacks specificity, there is clear evidence that these infections are responsible for 
true pneumonia defined by isolation of the organism from
3.2.2 Viral pneumonia—The study of viral pneumonia has been greatly enhanced by the 
use of PCR. A large case control study of paediatric hospital admissions for severe or very 
severe pneumonia (by WHO criteria) in Kenya in 2007 identified a number of viruses from a 
nasal wash specimen [51]. Consistent with other studies, the incidence of clinically 
diagnosed pneumonia was age-dependent, varying from 4.9% in the first year of life to 
<0.1% in children over the age of 5 years (Table 5). Respiratory syncytial virus (RSV) was 
detected in almost half of the infants and a third of the children with severe or very severe 
pneumonia, followed in frequency by human coronavirus (6.7%) and influenza virus type A 
(5.8%) while all others occurred at a frequency of less than 5%. In addition, RSV was 
responsible for a strong seasonal trend in pneumonia incidence (Table 6). Among the viruses 
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identified, only RSV was associated with severe disease (5% in control participants; 
adjusted odds ratio, 6.11 [95% CI 1.65-22.6])
A number of case-control studies have documented that both viral and bacterial respiratory 
pathogens are frequently isolated from the upper respiratory tract of healthy children and 
this underlines the importance of including well-matched controls in any study of the causes 
of respiratory illness in children. RSV and influenza virus are most consistently found to be 
significantly associated with respiratory illness compared to controls, although the odds of 
association may not be strong enough to be diagnostically useful [51–54]. With regard to 
other viruses, it seems likely that factors such as co-infection and density of infection may 
need to be considered and the lack of association between cases and controls does not 
exclude a virus as a cause of pneumonia.
There is evidence from various sources of the association between viral and bacterial 
pneumonia. There are anecdotal reports of lobar pneumonia in association with the 1918 
influenza pandemic and the H1N1 epidemic [55]. In a randomised, placebo-controlled trial 
of a 9-valent pneumococcal conjugate vaccine in South African infants, there was a 31% 
reduction in pneumonia associated with any of 7 respiratory viruses suggesting that infection 
with these viruses predisposes to pneumococcal pneumonia [56]. Immunological studies in 
mice suggest that infection with respiratory viruses impairs alveolar macrophage function 
for up to 10 days following infection and that this period was associated with severe and 
fatal bacterial pneumonia [57].
3.2.3 Blood stream infections—A study to identify bacterial causes of illness in sub-
Saharan Africa identified 22 published studies since 1980 of children admitted to hospital 
with a blood culture result [58]. Overall, 5,364 (12.3%) of 43,130 children had bloodstream 
infections. Of these, 1,643 (29.1%) non-malarial bloodstream infections were due to 
Salmonella enterica (of which 58.4% were due to NTS) and 1,031 (18.3%) were due to S. 
pneumoniae. The commonly reported organisms isolated from febrile children in Africa 
include S. pneumoniae (18.3%), NTS (17%), S. aureus (9.5%), and Escherichia coli (7.3%).
The available evidence suggests that bacteraemia is uncommon in children with non-severe 
illness since the prevalence of a positive aerobic blood culture is approximately 1% 
compared to an incidence of up to 15% among children needing hospital admission 
[4,13,20,59].
As alluded to above, a number of studies have described P. falciparum infection as a risk 
factor for blood stream infection with NTS and other Gram-negative infections. This 
association was first investigated in The Gambia where it was observed that children with 
malaria whose fever did not settle on quinine treatment often grew NTS from their blood 
culture and these infections were limited to the malaria transmission season while carriage 
of NTS by domestic animals was perennial [60]. Studies from Kenya and Tanzania have 
since found a high risk of NTS infection in children with a positive HRP-2 rapid test for 
malaria but a negative blood film for Plasmodium parasites, suggesting that vulnerability to 
these infections may persist for several weeks after an episode of malaria [13,20]. The 
association and direction of causality of malaria has been strengthened further by the finding 
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that the protection conferred by sickle cell trait (HbAS) against NTS is mediated by the 
protection against malaria associated with HbAS [22,61]. Immunological studies have 
extended the understanding of possible mechanisms of how malaria reduces immune 
responses to NTS [62]. A recent comparison between areas of high and low malaria 
transmission has described a striking contrast in risk factors for NTS and S. typhi, the latter 
appearing to infect older, non-HIV-infected children [63,64].
3.2.4 Atypical infections—In the context of this review, “atypical infection” is defined 
as infections not commonly isolated from aerobic blood culture. Knowledge of these 
infections in African children is limited, although increasing with the use of molecular 
diagnostics over the last decade. To investigate the frequency with which reports of these 
infections have been made, we used methods broadly the same as used by Reddy et al [58] 
and searched PubMed for reports of infection in Africa published between 1980 and 2014 of 
illness due to organisms not commonly isolated from blood culture. For practical reasons no 
age restriction was placed on the search, although papers that specifically referred to HIV-
infected patients were excluded. A total of 389 reports met the inclusion criteria. The 
number of these reports for each infection provides only an approximate indication of 
incidence since the decision to report an infection depends on factors such as rarity, 
scientific interest, severity etc. However, evidence from a recent study in Tanzania suggests 
that some of these infections (e.g. leptospirosis, Q fever) may be relatively common, hence 
further studies including comparison with healthy controls and regional differences are 
indicated [65].
4. Discussion
The currently increasing attention to diseases that until now have been relatively neglected is 
encouraging, especially since a number of studies have shown that among hospitalised 
children with fever a negative malaria slide is generally associated with higher mortality. 
However, the recent attention to NMFI might lead some to think that a new epidemic has 
been discovered while in truth this is an “epidemic of awareness” of infections that have 
been present but neglected for a long time. In reality, the decline in malaria incidence has 
been associated with a reduction in invasive bacterial disease, particularly NTS infection. 
Falling incidence of malaria is by no means universal [66,67]. In many areas it is providing 
an opportunity to improve diagnostic accuracy and improved quality of care, but this process 
needs to be accompanied by improved surveillance of febrile illness and the antimicrobial 
susceptibilities of its causes.
4.1 The usefulness of knowing the causes of NMFI
There are a number of important reasons to know the local diagnostic probabilities of 
common causes of fever, the main one being the need for a guide to pragmatic treatment. 
However, there are very few effective interventions available for the treatment of sick 
children in African hospitals; the key treatment decision based on the likely pathogen is still 
limited to the use of an antibiotic and, if so, which one. More specific diagnostic information 
is usually limited to the results of a blood culture (not routinely available in most African 
hospitals and not available for the critical first 24–48 hours of admission).
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Biomarkers to discriminate between blood stream bacterial compared to viral infection are 
still of limited clinical use. The reasons are that current tests that are available and 
affordable to most African hospitals lack sufficient sensitivity and specificity for routine use 
[42]. In non-severe illness, the proportion of children with a blood stream bacterial infection 
is approximately 1–3% [4,59] so that unless the specificity of a test is high, the predictive 
value of a positive test will be small and large numbers of antibiotic treatments will be given 
needlessly. In addition, a large number of tests with significant costs per test will be used to 
detect a small number of positives. By contrast, in children with severe illness the 
probability of a bacterial blood stream infection is relatively high and these infections are 
associated with significant mortality [13,68]. Thus, unless the sensitivity of the RDT is very 
high, a clinician would not be justified in withholding an antibiotic on the basis of a negative 
RDT for bacterial infection. The current WHO criteria for antibiotic treatment in severely ill 
children also suffer from lack of sensitivity and many clinicians would feel justified in 
prescribing antibiotics to all severely ill children, at least for the first 24–48 hours of 
admission, until blood culture results are known and during the period in which the majority 
of deaths in paediatric wards in Africa occur [13,68,69]. There is clearly a need to improve 
guidelines for care, particularly through incorporating quality-controlled laboratory results 
or “point of care” diagnostics into routine care.
4.2 Disease surveillance and control
There are additional public health reasons for a much more comprehensive knowledge of 
what infections are prevalent and where. These include the need to guide the deployment of 
vaccines or other preventive strategies. In addition, sentinel sites can identify emerging 
infections and, in particular, epidemic or pandemic threats to sub-Saharan Africa. This is 
increasingly important with growing global travel both into and out of the African continent.
4.3 Future trends
Child mortality is declining in Africa due to a number of reasons but the decline in malaria 
transmission intensity and the introduction of vaccines against Hib and pneumococcal 
disease are important contributors. There is an additional benefit to malaria control in that up 
to half of all blood stream bacterial infections in African children are caused by NTS and 
these infections become rare in children at low levels of malaria transmission, although may 
still be seen in HIV-infected adults [22,63]. This “added value” to malaria control could well 
account for the fact that malaria control has often been followed by greater than expected 
reductions in child mortality [70]. New vaccines, particularly against meningococcal disease 
and RSV are likely to have additional benefits to child survival in Africa.
These trends are very positive but one worrying effect of improvement in the diagnosis of 
malaria has been an increase in the prescription of antibiotics, which is likely to increase the 
already high levels of resistance to affordable antibiotics in Africa [13]. There is a need to 
more accurately define indications for antibiotic treatment in African children with non-
severe illness and to review the use of amoxicillin in children with WHO criteria of “non-
severe pneumonia”, especially in a scenario where the incidence of bacterial pneumonia is 
declining.
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Table 1
Studies of pneumonia in children contributing to World Health Organization (WHO) clinical case definitions
Study Site Sample size Gold standard
pneumonia
definition
Clinical signs/symptoms
investigated
Conclusions regarding
definition
Shann et al 
[28]
Goroka, Papua New 
Guinea
350 Crepitations on auscultation Age, RR, lower chest wall 
indrawing, cyanosis, 
wheeze, pulse rate, 
palpable liver, 
temperature >37.5°C, 
feeds poorly
RR >50/minute was the 
most accurate way to 
differentiate pneumonia 
from nonpneumonia
Cherian et 
al [29]
Vellore, Tamil Nadu, 
India
682 Crepitations, wheeze, 
bronchial breathing or 
radiological abnormalities
RR, parental report of 
rapid breathing, 
intercostal retraction
Refined the value of RR 
by age stratification to 
>50 for infants and >40 
for children >12 months
Campbell 
et al [30]
Banjul, The Gambia 222 
(episodes of 
illness in a 
cohort 
study)
Radiological signs (lobar 
consolidation)
Vomiting, rapid breathing, 
refusing to feed, chest 
indrawing, RR, nasal 
flaring, temperature, heart 
rate, crepitations, 
bronchial breathing or 
reduced air entry, rhonchi, 
grunting
Temperature >38.5°C, 
refusing to feed and 
vomiting were the most 
useful predictors of 
severe pneumonia in 
infants, whereas 
temperature >38.5°C and 
RR >60/minute were the 
most useful among 
children aged 1–4 years 
old
Mulholland 
et al [31]
Philippines, Swaziland 730 Complete history, physical 
examination by 
paediatrician, and CXR
Cough, difficulty 
breathing, chest wall 
indrawing, RR. Cases 
with wheeze excluded
Sensitivity and 
specificity for RR >40/
minute or for lower chest 
wall indrawing were 
between 0.77 and 0.81 in 
2 different settings, but 
specificity was lower 
when judged by a 
healthcare worker
Simoes and 
McGrath 
[32]
Mbabane, Swaziland 362 Paediatrician’s assessment 
on WHO criteria
Cough, difficulty 
breathing, ability to drink/
feed well, convulsions, 
abnormal sleepiness, 
stridor, severe 
undernutrition, fever, 
wheeze, lower chest wall 
indrawing, tachypnoea, 
fever
Using RR and lower 
chest wall indrawing, 
nurses and nursing 
assistants detected 71%–
83% of pneumonia cases 
with specificity of 84%–
85%
CXR, chest radiograph; RR, respiratory rate
Reproduced from Scott et al [33]
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Table 2
Examples of varying definitions of severe pneumonia depending on purpose
Source Very severe pneumonia Severe pneumonia Purpose
WHO [25] CDB+ multiple convulsions or coma or lethargy 
or vomiting everything or inability to drink or 
cyanosis or severe respiratory distress
CDB+ chest indrawing Treatment of children with 
suspected pneumonia
Cutts et al [34] Clinically suspected pneumonia with 
radiological opaque or fluffy opacities 
in part or all of a lobe of the lung or 
pleural effusion
Clinical trial of 
pneumococcal vaccine
Nokes et al [35] As severe but >2 criteria needed CDB+ >1 of: intercostal indrawing, 
inability to feed, increased RR for age, 
SPO2 <90%
Epidemiological 
description of admitted 
cases
Scott et al [33] CDB+ any of: hypoxaemia (SPO2 <90%), 
inability to feed, head nodding, or impaired 
consciousness
CDB+ chest indrawing Epidemiological 
description of admitted 
cases
Nair et al [23] As severe, + any IMCI danger sign or 
hypoxaemia (SPO2 <90%)
CDB+ admitted to hospital Estimation of global 
burden
Mulholland et al 
[36]
Invasive Hib disease verified by positive isolate 
from blood or CSF culture
Randomised clinical trial 
of Hib vaccine
CDB+, cough/difficulty breathing plus; IMCI, integrated management of childhood illnesses; SpO2, saturation of peripheral oxygen; RR, 
respiratory rate; Hib, Haemophilus influenzae type b; CSF, cerebral spinal fluid; WHO, World Health Organization
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Table 3
Child Health Epidemiology Reference Group (CHERG) estimates of pneumonia in children 0–4 years of age 
in countries in the World Health Organization (WHO) Africa region shown as national level totals (incidence) 
and by causative pathogens; estimates of the number of new severe episodes (according to WHO’s definition) 
in the year 2010 that require hospitalisations, shown as national level totals (severe episodes, all ALRI) and by 
causative pathogens; and estimates of the number of child deaths attributable to pneumonia in 2011 (mortality, 
all ALRI) and the proportion of deaths caused by causative pathogens.
Population 0–4 years = 134,240,762
Number of cases Incidence/year % of cases
All ALRI 36,412,108 0.271 (0.213-0.338)a 100
Of which:
  Streptococcus pneumoniae 2,575,393 0.019 (0.015-0.022) 7.1
 Haemophilus influenzae type b 780,756 0.006 (0.003-0.006) 2.1
 Respiratory syncytial virus 10,501,165 0.078 (0.061-0.090) 28.8
 Influenza virus 6,215,546 0.046 (0.056-0.053) 17.1
Other cause estimates not available
Severe ALRI (severe morbidity)
Of which:
4,166,781 0.031 (0.018-0.036) 100
  Streptococcus pneumoniae 761,241 0.006 (0.004-0.007) 18
 Haemophilus influenzae type b 130,134 0.001 (0.0005-0.001) 3
 Respiratory syncytial virus 558,669 0.004 (0.003-0.005) 13
 Influenza virus 171,931 0.001 (0.001-0.002) 4
Other cause estimates not available
ALRI Deaths (morbidity)
Of which:
531,451 0.004 (0.002-0.005) 100
  Streptococcus pneumoniae 173,896 0.0013 (0.001-0.002) 33
 Haemophilus influenzae type b 42,404 0.0003 (0.0001-0.0004) 8
Other cause estimates not available
ALRI, acute lower respiratory infection;
a
Interquartile range of incidences in 46 WHO-Afro countries
Adapted from Rudan et al [24]
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Table 4
Aetiology of radiologically confirmed pneumonia in Malawian children in 2011 using different laboratory 
methods
No. HIV+ (%)
Blood
culture
Lung aspirate
culture
Lung aspirate
latex
Lung aspirate
PCR
Bacterial aeteology
 Total 45 8 2 4 36
  Streptococcus pneumoniae 37 68 6 1 3 31
  Streptococcus pneumoniae /
  Streptococcus typhimurium 2 0 2 1 0 NT
 Haemophilus influenzae type b 6 67 0 0 1 5
Viral aeteology
 Total 24 NT NT NT 24
 Adenovirus 15 53 NT NT NT 15
 Bocavirus 4 50 NT NT NT 4
 Cytomegalovirus 3 100 NT NT NT 3
Atypical
  Chlamydia pneumoniae 2 0 NT NT NT 2
  Mycoplasma pneumoniae 0 NT NT NT 0
Pneumocystis jirovecii 3 100 NT NT NT 3
NT, not tested; PCP, pneumocystis pneumonia; Hib, Haemophilus influenzae type b; CMV, cytomegalovirus; HIV, human immunodeficiency 
virus; PCR, polymerase chain reaction
Bacteria: 2 patients had mixed infection with S. typhimurium and S. pneumoniae; 1 had S. typhimurium from blood culture and S. pneumoniae 
from blood PCR, and adenovirus from lung aspirate PCR, 1 had S. typhimurium from blood and lung aspirate culture and S. pneumoniae from lung 
aspirate PCR, 7 had S. pneumoniae/adenovirus, 1 had S. pneumoniae/chlamydia, 1 case with S. pneumoniae had Mycobacterium tuberculosis 
cultured from nasopharyngeal aspirate after induced sputum.
Pneumocystis: 1 patient had PCP/Hib, 1 patient had PCP/CMV, 1 patient had PCP/adenovirus
Viruses: 1 adenovirus/CMV, 1 adenovirus/chlamydia, 1 bocavirus/CMV
Reproduced from Carrol et al [42]
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Table 5
Incidence of admission to a Kenyan district hospital with “severe pneumonia” or “very severe pneumonia” 
and viruses identified by polymerase chain reaction of nasal wash
Age Group under 28 days
All
<1 y
1 to
1.99 y
2 to
4.99 y
All
<5 y
5 to
12.99 y
All
<13 y
Denominator 9,423 births 8,837 44,538 104,505
per 1,000 live births per 100,000 children/y
‘Severe’ or ‘very severe’
pneumonia 6.65 4,798 1,674 543 1,522 99 681
Any respiratory virus 3.79 2,993 871 213 862 36 380
Respiratory syncytial virus 2.46 2,038 455 85 535 15 233
Human coronavirus 229E 0.51 318 135 32 105 3 46
Influenza A 0.31 244 97 32 82 15 39
Human parainfluenza virus 0.10 212 48 11 57 6 26
Adenovirus 0.10 149 77 21 55 9 26
Human metapneumovirus 0.20 138 58 11 44 6 21
Reproduced from Berkley et al [51]
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